American Journal of Ophthalmology
Volume 150, Issue 2 , Pages 144-162.e2, August 2010

Nanomedicine in Ophthalmology: The New Frontier

  • Marco A. Zarbin

      Affiliations

    • Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey
    • Corresponding Author InformationInquiries to Marco A. Zarbin, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Room 6155, Doctors Office Center, 90 Bergen St, Newark, NJ 07103
  • ,
  • Carlo Montemagno

      Affiliations

    • College of Engineering, University of Cincinnati, Cincinnati, Ohio
  • ,
  • James F. Leary

      Affiliations

    • Purdue University, West Lafayette, Indiana
  • ,
  • Robert Ritch

      Affiliations

    • New York Eye & Ear Infirmary, New York, New York

Accepted 10 March 2010.

Purpose

To review the fields of nanotechnology and nanomedicine as they relate to the development of treatments for vision-threatening disorders.

Design

Perspective following literature review.

Methods

Analysis of relevant publications in the peer-reviewed scientific literature.

Results

Nanotechnology involves the creation and use of materials and devices at the size scale of intracellular structures and molecules and involves systems and constructs on the order of <100 nm. The aim of nanomedicine is the comprehensive monitoring, control, construction, repair, defense, and improvement of human biological systems at the molecular level, using engineered nanodevices and nanostructures, operating massively in parallel at the single cell level, ultimately to achieve medical benefit. The earliest impact of nanomedicine is likely to involve the areas of biopharmaceuticals (eg, drug delivery, drug discovery), implantable materials (eg, tissue regeneration scaffolds, bioresorbable materials), implantable devices (eg, intraocular pressure monitors, glaucoma drainage valves), and diagnostic tools (eg, genetic testing, imaging, intraocular pressure monitoring). Nanotechnology will bring about the development of regenerative medicine (ie, replacement and improvement of cells, tissues, and organs), ultrahigh-resolution in vivo imaging, microsensors and feedback devices, and artificial vision. “Regenerative nanomedicine,” a new subfield of nanomedicine, uses nanoparticles containing gene transcription factors and other modulating molecules that allow for the reprogramming of cells in vivo.

Conclusions

Nanotechnology already has been applied to the measurement and treatment of different disease states in ophthalmology (including early- and late-stage disease), and many additional innovations will occur during the next century.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9394(10)00233-3

doi:10.1016/j.ajo.2010.03.019

American Journal of Ophthalmology
Volume 150, Issue 2 , Pages 144-162.e2, August 2010